

Coulter:Partners

Top hires for VC & PE portfolio companies Q3-2020

Search Highlights

This quarter's successful placements include:

- CEO, vaccines, UK
- CEO, medical devices, Germany
- Chief Financial Officer (US-based), rare diseases, Denmark
- Chief Financial Officer, medical devices, US
- VP Research, rare diseases, UK
- VP Discovery, cell therapy, Singapore
- VP Engineering, medical devices, Switzerland
- VP Business Development & Licensing US, genome editing, Ireland
- Head of Regulatory Affairs, diagnostics, UK
- Head of CMC, immuno-oncology, Singapore
- Head of US Sales & Business Development, recombinant products, UK
- Marketing Director APAC, surgical devices, France
- Site Leader Manufacturing Operations France, CDMO, US
- Chair, CNS diseases, Belgium

Newly opened projects include:

- CEO, haemostasis therapeutics, Netherlands
- Chief Human Resources Officer, surgical implants, US
- Chief Business Officer, CNS diseases, US
- Chief Scientific Officer, gene therapy, UK
- Chief Development Officer, vaccines, Switzerland
- Head of Growth/ Chief Marketing Officer, digital health, Germany
- VP Business Development UK & Europe, drug delivery, US
- VP Industrial Operations Europe, consumer health, US
- VP Product Development, vaccines, US
- VP Commercial Europe, in vitro diagnostic products, Israel
- VP Business Development US, oncology, Singapore
- Head of Data & Analytics, antibody therapeutics, UK
- Chair, drug delivery, UK

Themes

Areas of focus this quarter include, but are not limited to:

- Cell & Gene Therapy
- Vaccines
- Immunology
- Digital Health
- Oncology
- CNS
- Haematology
- Infectious Diseases
- Regenerative Medicine

www.coulterpartners.com